According to scientists from the U.K., a drug to treat Alzheimer’s disease may be available within the next five years!

Scientists in the U.S. are currently recruiting participants aged 55 to 90 for the final stages of the study. During the study, researchers will examine whether the drug solanezumab slows the functional and cognitive decline of patients who struggle with mild Alzheimer’s. For the last trial, participants will be given the drug as a monthly 400 mg injection for a period of 18 months.

Dr. Eric Karran, director of research at Alzheimer’s Research UK, says scientists believe this study could provide a breakthrough in treatment for people who struggle with the disease. Previous trials for the drug, have found that while there was no effect in people with later stages of the disease, they did find an effect in the daily behaviors and functioning of the brain and memory in people who are experiencing the earlier stages of the disease.

Researchers are expecting the trial to end in December 2016.